为解决 FLT3 突变的急性髓系白血病（AML）治疗耐药问题，研究人员开展 FHD-286 与 FLT3 抑制剂联合治疗研究，发现联合治疗增效显著，有重要临床意义。 为了攻克这一难题，美国德克萨斯大学 MD 安德森癌症中心（The University of Texas M.D. Anderson Cancer Center）的研究人员展开了深入研究。他们的研究成果发表在《Blood Cancer ...

Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment TA1036 5 February 2025 5 February 2025 Ganaxolone for treating ...

The Japanese regulator has approved Daiichi Sankyo’s quizartinib for certain patients with acute myeloid leukaemia (AML), amid doubts over the outcome of a regulatory review in the US.